Loading...
Loading...
BTX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 63.0K |
| Gross Profit | -63.0K |
| Operating Expense | 4,089.0K |
| Operating I/L | -4,549.0K |
| Other Income/Expense | 45.0K |
| Interest Income | 24.0K |
| Pretax | -4,504.0K |
| Income Tax Expense | 4.0K |
| Net Income/Loss | -4,508.0K |
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Its flagship program, IRX-2, is currently undergoing a Phase 2b clinical trial for patients with squamous cell cancer of the head and neck. The company also leverages gene-editing and cell therapy technology to develop treatments for oncology, blood disorders, and monogenic diseases, catering to a diverse range of medical needs.
